<DOC>
	<DOCNO>NCT02495077</DOCNO>
	<brief_summary>During transplant surgery , period time donate kidney remove donor 's body store time transplant surgery . The storage procedure result buildup various protein within kidney injure donate kidney transplant . One proteins tumor necrosis factor-alpha ( TNF-alpha ) . The purpose study evaluate whether take infliximab , block TNF-alpha , prior transplant surgery along usual transplant medicine protect donate kidney damage cause TNF-alpha help keep transplanted kidney healthy long period time .</brief_summary>
	<brief_title>Effects Inhibiting Early Inflammation Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>1 . Subject must able understand provide consent 2 . Recipients decease donor kidney transplant 3 . Recipients HLA mismatch kidney 4 . Recipients virtual cross match negative determine local HLA lab 5 . Donor kidney decease donor donor cardiac death ( DCD ) Kidney Donor Profile Indices ( KDPI ) range &gt; 35 &lt; 95 6 . Female participant childbearing potential must negative pregnancy test upon study entry 1 . Inability unwillingness participant give write informed consent comply study protocol 2 . Recipients live donor transplant 3 . Presence transplant organ cotransplanted organ 4 . Recipients kidneys zero HLA mismatch 5 . HIV+ recipients 6 . EBV negative recipient 7 . Hepatitis B surface antigen positive kidney transplant recipients 8 . Hepatitis B core antibody positive kidney transplant recipients 9 . Hepatitis B negative kidney transplant recipient receive transplant Hepatitis B core antibody positive donor 10 . Hepatitis C Virus positive ( HCV+ ) patient either untreated fail demonstrate sustain viral remission 12 month antiviral treatment 11 . Recipients previous history active TB 12 . Patients positive test TB exposure ( PPD , QuantiFERON , ELISPOT ) without history active infection NOT complete full course INH therapy 13 . Recipients positive virtual cross match determine local HLA lab 14 . Any infection time transplantation 15 . Severe congestive heart failure ( NYHA functional class III high ) 16 . Subjects know hypersensitivity murine/ mouse proteins . 17 . Subjects history receive antiTNF product 18 . Subjects rATG infliximab might tolerate 19 . Subjects less 3000/mm^3 WBC 20 . Subjects less 100,000/mm^3 platelet count 21 . Subjects systolic blood pressure &lt; 100 mm/Hg 22 . Subjects symptomatic orthostatic hypotension currently require Midodrine blood pressure support 23 . Subjects travel endemic area history active histoplasmosis CXR consistent previous active histoplasmosis ( serological testing require ) . 24 . Subjects currently formerly reside region US highly endemic coccidioidomycosis , positive serologic test coccidioidomycosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>infliximab</keyword>
	<keyword>Tissue Donors</keyword>
	<keyword>Remicade</keyword>
	<keyword>Induction Therapy</keyword>
	<keyword>Deceased Donor Kidney Transplant Recipients</keyword>
</DOC>